Embla Medical hf. (LON:0FIW)

London flag London · Delayed Price · Currency is GBP · Price in DKK
27.83
0.00 (0.00%)
At close: May 29, 2026
Market Cap1.33B -6.8%
Revenue (ttm)725.72M +11.7%
Net Income64.85M +18.6%
EPS0.15 +19.1%
Shares Out n/a
PE Ratio20.53
Forward PE18.47
Dividendn/a
Ex-Dividend Daten/a
Volume24
Open27.83
Previous Closen/a
Day's Range27.83 - 27.83
52-Week Range25.90 - 36.40
Beta0.58
Analystsn/a
Price Targetn/a
Earnings DateJul 21, 2026

About Embla Medical

Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides os... [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Founded 1971
Employees 4,500
Stock Exchange London Stock Exchange
Ticker Symbol 0FIW

Financial Performance

In 2025, Embla Medical's revenue was $928.69 million, an increase of 8.63% compared to the previous year's $854.89 million. Earnings were $83.34 million, an increase of 22.05%.

Financial numbers in USD Financial Statements

News

Embla Medical Earnings Call Transcript: Q1 2026

Q1 2026 saw 15% revenue growth (4% organic), stable margins despite tariffs and FX, and 21% bottom-line growth. Guidance for 5%-8% organic growth and 20%-22% EBITDA margin is reiterated, with segment strength in Prosthetics and neuro-orthotics and recovery expected in Patient Care.

5 weeks ago - Transcripts

Embla Medical Quarterly report: Q1 2026

Embla Medical has published its Q1 2026 quarterly earnings report on April 28, 2026.

5 weeks ago - Filings

Embla Medical Slides: Q1 2026

Embla Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.

5 weeks ago - Filings

Embla Medical Earnings Call Transcript: Q1 2026

Q1 2026 saw 15% reported sales growth and 21% net profit growth, with strong Prosthetics & Neuro Orthotics performance and margin pressure from FX and tariffs. Full-year guidance for 5%-8% organic growth and 20%-22% EBITDA margin is reiterated.

5 weeks ago - Transcripts

Embla Medical Quarterly report: Q1 2026

Embla Medical has published its Q1 2026 quarterly earnings report on April 28, 2026.

5 weeks ago - Filings

Embla Medical Slides: Q1 2026

Embla Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.

5 weeks ago - Filings

Embla Medical Slides: Investor presentation

Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.

5 weeks ago - Filings

Embla Medical Transcript: Life Science-dagen 2026

A global leader in mobility solutions is driving growth through innovation, acquisitions, and expanding access to advanced prosthetics and neuro-orthotics. Key growth comes from functional trade-up, recurring sales, and new market penetration, while challenges include reimbursement, tariffs, and geopolitical risks.

3 months ago - Transcripts

Embla Medical Slides: FY 2026

Embla Medical has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 4, 2026.

3 months ago - Filings

Embla Medical Earnings Call Transcript: Q4 2025

Solid organic and acquisition-driven growth was achieved, with strong cash flow and resilient margins despite tariffs and FX headwinds. Guidance for 2026 anticipates 5%-8% organic growth and 20%-22% EBITDA margin, supported by efficiency gains and new product launches.

4 months ago - Transcripts

Embla Medical Annual report: Q4 2025

Embla Medical has published its Q4 2025 annual report on February 3, 2026.

4 months ago - Filings

Embla Medical Quarterly report: Q4 2025

Embla Medical has published its Q4 2025 quarterly earnings report on February 3, 2026.

4 months ago - Filings

Embla Medical Slides: Q4 2025

Embla Medical has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.

4 months ago - Filings

Embla Medical Earnings Call Transcript: Q4 2025

Solid organic sales growth and profitability were achieved in 2025, driven by strong performance in prosthetics and neuroorthotics, with robust cash flow and margin resilience despite FX and tariff headwinds. 2026 guidance targets 5%-8% organic growth and 20%-22% EBITDA margin.

4 months ago - Transcripts

Embla Medical Annual report: Q4 2025

Embla Medical has published its Q4 2025 annual report on February 3, 2026.

4 months ago - Filings

Embla Medical Quarterly report: Q4 2025

Embla Medical has published its Q4 2025 quarterly earnings report on February 3, 2026.

4 months ago - Filings

Embla Medical Slides: Q4 2025

Embla Medical has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.

4 months ago - Filings

Embla Medical Slides: Investor presentation

Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on February 3, 2026.

4 months ago - Filings

Embla Medical hf: Interim Report Q4 and Full Year 2025

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full Year 2025 Sveinn Sölvason, President and CEO, comments: "We delivered solid sales in the fourth qua...

4 months ago - PRNewsWire

Embla Medical Slides: SEB Nordic Seminar presentation

Embla Medical has posted slides in relation to its latest quarterly earnings report, which was published on January 9, 2026.

5 months ago - Filings

Embla Medical Earnings Call Transcript: Q3 2025

Q3 2025 saw 7% organic and 11% reported sales growth, led by double-digit gains in prosthetics and neuroorthotics, while patient care and bracing/supports lagged. EBITDA margin held at 22%, and full-year guidance for 5%-6% organic growth and 20%-21% EBITDA margin was reiterated.

8 months ago - Transcripts

Embla Medical Quarterly report: Q3 2025

Embla Medical has published its Q3 2025 quarterly earnings report on October 21, 2025.

8 months ago - Filings

Embla Medical Slides: Q3 2025

Embla Medical has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 21, 2025.

8 months ago - Filings

Embla Medical Earnings Call Transcript: Q3 2025

Q3 2025 saw 7% organic sales growth, led by double-digit gains in prosthetics and new orthotics, with EBITDA margin at 22%. Guidance for 5%-6% organic growth and 20%-21% EBITDA margin is reiterated, while tariffs and internal changes impact patient care and bracing segments.

8 months ago - Transcripts

Embla Medical Quarterly report: Q3 2025

Embla Medical has published its Q3 2025 quarterly earnings report on October 21, 2025.

8 months ago - Filings